Average Insider

Where insiders trade, we follow

$DFTX
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Robert Barrow
CEO
74
Employees
$18.40
Current Price
$1.64B
Market Cap
52W Low$12.88
Current$18.4081.8% above low, 18.2% below high
52W High$19.63

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00--All Sells
Sells33$560,938.7842,667
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Dec 26, 2025
Karlin Daniel
Chief Medical Officer
Sale5,600$13.15$73,622.64View Details
Dec 26, 2025
Barrow Robert
Director
Sale25,791$13.15$339,071.70View Details
Dec 26, 2025
Sullivan Mark
Chief Legal Officer
Sale11,276$13.15$148,244.44View Details
10 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
May 6, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Mar 5, 2026
EPS
Estimated-$0.45
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.3.23